Alprazolam

Mechanism

Additive bradycardia and hypotension. Alprazolam sedation may mask early symptoms of excessive blood pressure drop.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk. With additional antihypertensives: bradycardia (pulse below 60/min).

Management

The combination is acceptable for short alprazolam use with pulse and blood pressure monitoring. In older patients, lorazepam at minimum doses is preferable with fall risk warning.

Mechanism

Bupropion lowers seizure threshold, especially at high doses (above 300 mg/day) or in predisposition. Abrupt alprazolam withdrawal further raises seizure risk via GABAergic rebound.

Symptoms

Tremor, jitters, severe cases: seizures. Symptoms appear with bupropion up-titration or abrupt alprazolam withdrawal. In epilepsy or prior head trauma, risk is maximal.

Management

Avoid in epilepsy and prior head trauma. If unavoidable (nicotine dependence with anxiety), start bupropion at 150 mg in the morning and do not exceed 300 mg/day. Do not stop alprazolam abruptly — taper over 4–8 weeks.

Mechanism

Additive hypotension. Alprazolam sedation may mask early orthostatic symptoms.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check standing and sitting blood pressure 1–2 weeks after start. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive hypotension and sedation. Carvedilol's α/β-blockade causes fatigue and dizziness on its own; alprazolam adds GABAergic CNS depression.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Postural dizziness, syncope, fatigue. Older patients: fall and fracture risk.

Management

On starting the combination, begin alprazolam at the minimum dose (0.25 mg at bedtime). In older patients, cap at 0.5 mg/day. Check standing/sitting BP at one week. With pronounced sedation, consider non-drug options for anxiety (CBT, breathing exercises) or switch to buspirone (no sedation).

Mechanism

Additive sedation. Cetirizine is a second-generation antihistamine with minimal blood-brain barrier penetration, but the effect adds up with alprazolam.

Symptoms

Drowsiness, sedation, ataxia. Older patients: fall risk. Symptoms appear in the first 1–2 days.

Management

Warn the patient about drowsiness, especially with the first dose. Alternative antihistamines with minimal sedation: fexofenadine or bilastine. In patients needing alprazolam, take antihistamines during the day, not at bedtime.

Mechanism

Additive CNS depression. Citalopram does not inhibit CYP3A4 — no pharmacokinetic interaction with alprazolam. The effect adds up at GABA and serotonin receptors.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.

Management

On starting the combination, begin alprazolam at the minimum dose. In older patients, cap citalopram at 20 mg/day (QT risk) and alprazolam at 0.5 mg/day. For long-term anxiety treatment, plan CBT as the core therapy with gradual benzodiazepine taper.

Mechanism

Additive CNS depression and hypotension. Clonidine is a central α2-agonist with sedative effect; alprazolam is a GABAergic sedative.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Pronounced morning hypotension and bradycardia possible.

Management

On starting the combination, begin both at minimal doses with time-separated dosing (e.g. clonidine in the morning, alprazolam at bedtime). Avoid the combination in older patients — fall risk. In anxiety disorders with hypertension, alternative: a beta-blocker (metoprolol) plus buspirone.

Mechanism

Diltiazem moderately inhibits CYP3A4; alprazolam is a CYP3A4 substrate. Alprazolam AUC rises by 30–50%, prolonging sedation.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Morning sedation is especially pronounced (alprazolam half-life is extended).

Management

On starting the combination, reduce alprazolam by 25–50%. In older patients, start at 0.125 mg at bedtime. Antihypertensive alternatives: amlodipine or a beta-blocker without CYP3A4 effect (metoprolol, bisoprolol). Anxiolytic alternatives: lorazepam or oxazepam (CYP3A4-independent), or buspirone.

Mechanism

Additive CNS depression. Duloxetine weakly inhibits CYP2D6 with no CYP3A4 effect — no pharmacokinetic interaction with alprazolam.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.

Management

On starting the combination, begin alprazolam at the minimum dose. In anxiety with chronic pain (neuropathy, fibromyalgia), the combination is reasonable, but for long-term therapy assess feasibility of benzodiazepine discontinuation via CBT. Avoid the combination in older patients — fall risk.

Mechanism

Additive hypotension. Alprazolam sedation may mask orthostatic symptoms.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check standing and sitting blood pressure 1–2 weeks after start. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive sedation. No direct pharmacokinetic interaction – escitalopram does not significantly block CYP3A4.

Symptoms

Additional drowsiness, ataxia in the first 1–2 weeks. Older patients: fall risk.

Management

Widely used in anxious-depressive disorders. Alprazolam is given for a short course (4–6 weeks) with gradual taper after escitalopram's effect stabilises. In older patients: minimum alprazolam dose; monitor cognition.

Mechanism

Fluvoxamine inhibits CYP3A4 and CYP1A2. Alprazolam is a CYP3A4 substrate. Alprazolam AUC rises by 50–100%; half-life doubles.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Morning sedation is especially pronounced.

Management

Avoid the combination. If unavoidable, halve the alprazolam dose and give only at bedtime. Do not prescribe in older patients. Anxiolytic alternatives: buspirone, lorazepam, or oxazepam (CYP3A4-independent). Antidepressant alternatives: sertraline or escitalopram (minimal CYP3A4 effect).

Mechanism

Additive hypotension and fall risk in older patients. No direct pharmacokinetic interaction.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check standing and sitting blood pressure 1–2 weeks after starting alprazolam. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive CNS depression via different mechanisms: alprazolam (GABAergic) and gabapentin (α2δ calcium channel inhibition). Sedation, ataxia, and fall risk amplify.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Ataxia and fall risk are especially pronounced in older patients.

Management

On starting the combination, begin both at minimal doses. Avoid the combination in older patients — fall and fracture risk. In neuropathic pain and anxiety, alternative: low-dose amitriptyline (10–25 mg at bedtime) with buspirone. If unavoidable, watch for sedation signs and check heart rate and BP at one week.

Mechanism

Additive CNS depression and sedation. In older patients: high delirium and fall risk.

Symptoms

Deep sedation, drowsiness, ataxia, confusion (especially in older patients). Orthostatic hypotension possible (haloperidol blocks α1-adrenoceptors).

Management

The combination is used briefly in acute agitation or psychotic episodes. In older patients: lorazepam at minimum dose with olanzapine or aripiprazole (less α1-blockade than haloperidol) is preferable.

Mechanism

Additive hypotension and fall risk. No direct pharmacokinetic interaction.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check standing and sitting blood pressure 1–2 weeks after start. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive hypotension and fall risk in older patients. Additional delirium risk with diuretic-induced hypovolaemia.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check standing and sitting blood pressure 1–2 weeks after start; assess fluid and electrolyte balance. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive CNS depression and sedation. No direct pharmacokinetic interaction – levetiracetam is not CYP-metabolised.

Symptoms

Drowsiness, sedation, ataxia. Older patients: fall risk.

Management

The combination is acceptable when anticonvulsant and anxiolytic therapy are both needed. In older patients, monitor cognition and fall risk. Alternative anxiolytic with minimal sedation: a gabapentinoid (low-dose pregabalin) for anxiety.

Mechanism

Additive hypotension. Alprazolam sedation may mask orthostatic symptoms.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check standing and sitting blood pressure 1–2 weeks after start. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive bradycardia and sedation. Fall risk in older patients.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check pulse and blood pressure 1–2 weeks after starting alprazolam. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive sedation and fall risk in older patients. No direct pharmacokinetic interaction.

Symptoms

Deep sedation, drowsiness, ataxia. Older patients: fall and fracture risk. Symptoms appear in the first 1–2 weeks.

Management

Widely used in anxious-depressive disorders. Alprazolam is given for a short course (4–6 weeks) with gradual taper after mirtazapine's effect stabilises. In older patients: minimum alprazolam dose; monitor cognition.

Mechanism

Additive hypotension with sublingual nitroglycerin. Alprazolam sedation may worsen dizziness.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

The patient takes the first nitroglycerin dose sitting or lying down. Warn the patient about fall risk after nitroglycerin while on alprazolam.

Mechanism

Omeprazole weakly blocks CYP3A4; alprazolam plasma levels may rise slightly. The effect is clinically weak.

Symptoms

Minimal changes: mild additional sedation in some patients. Older patients: rare ataxia.

Management

Dose adjustment is usually unnecessary. In older patients and prolonged therapy, monitor cognition and fall risk.

Mechanism

Additive CNS depression via different mechanisms (GABAergic for alprazolam, α2δ calcium channel blockade for pregabalin). Sedation, ataxia, and fall risk amplify, especially in older patients.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Ataxia and fall risk are especially pronounced in older patients.

Management

On starting the combination, begin both at minimal doses. Avoid the combination in older patients — fall and fracture risk. In neuropathic pain and anxiety, alternative: low-dose amitriptyline with buspirone, or duloxetine with CBT. If unavoidable, give alprazolam only at bedtime.

Mechanism

Additive bradycardia, hypotension, and sedation. Propranolol is non-selective (blocks β1 and β2); risk higher than with bisoprolol.

Symptoms

Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.

Management

In older patients, check pulse and blood pressure 1–2 weeks after start. In asthma or COPD, a selective beta-blocker (bisoprolol, metoprolol) is preferable. Alternative anxiolytic: hydroxyzine or a short lorazepam course.

Mechanism

Additive CNS and respiratory depression. Both are sedating; the combination raises paradoxical respiratory suppression risk in older patients and in COPD.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. In COPD: dyspnoea, hypercapnia. Pronounced morning sedation possible.

Management

Avoid in older patients and in COPD. If unavoidable (anxiety with bipolar depression), cap alprazolam at 0.5 mg at bedtime and use the minimum quetiapine dose. In patients on stable quetiapine for sedation, adding alprazolam is not justified — increase quetiapine alone instead.

Mechanism

Tacrolimus is a weak CYP3A4 inhibitor; alprazolam is a CYP3A4 substrate. Alprazolam levels may rise moderately. Additive sedative effect.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.

Management

On starting the combination, begin alprazolam at 0.25 mg at bedtime. In transplant patients, prefer buspirone or CBT for anxiety over benzodiazepines. If unavoidable, tacrolimus monitoring is unchanged, but check sedation at 1 and 2 weeks after starting alprazolam.

Mechanism

Additive orthostatic hypotension. Tamsulosin (α1-blocker) directly vasodilates; alprazolam mildly lowers BP and amplifies the orthostatic response.

Symptoms

Postural dizziness, syncope, fatigue. Older patients: fall and fracture risk. Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.

Management

On starting the combination, take tamsulosin in the evening (to minimise daytime weakness) and alprazolam at bedtime. In older patients, start alprazolam at 0.125 mg. Check standing/sitting BP at 1 and 2 weeks. With pronounced orthostatic hypotension, consider switching tamsulosin to silodosin (minimal BP effect).

Mechanism

Additive hypotension. Benzodiazepines have weak hypotensive effect; the main one comes from the ARB. In most patients, clinically minor.

Symptoms

Postural dizziness, syncope, fatigue. Older patients: fall and fracture risk. Morning weakness possible at standard doses.

Management

No dose adjustment usually needed. In older patients on starting telmisartan, check standing/sitting BP at one week. With pronounced morning hypotension, move alprazolam from night to morning or switch to buspirone.

Mechanism

Valproate weakly suppresses hepatic alprazolam metabolism; alprazolam plasma levels may rise slightly. Plus additive sedation.

Symptoms

Additional drowsiness, ataxia. Older patients: fall risk. Symptoms appear in the first 1–2 weeks.

Management

Reduce alprazolam by 25% if needed. In older patients and prolonged therapy, monitor cognition and fall risk. Alternative anxiolytic without CYP dependence: lorazepam or oxazepam.

Mechanism

Additive CNS depression (minimal for venlafaxine, mainly from alprazolam). High-dose venlafaxine (above 150 mg/day) also raises BP.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.

Management

On starting the combination, begin alprazolam at the minimum dose. For long-term anxiety treatment, prioritise antidepressant monotherapy with CBT and gradual benzodiazepine taper. In arterial hypertension, check BP 2 weeks after starting venlafaxine.